Coherus Oncology announced that its anti‑CCR8 antibody tagmokitug (CHS‑114) was published in the December 2025 issue of Molecular Cancer Therapeutics. The paper reports picomolar binding affinity, complete selectivity for CCR8, and potent target‑cell killing in preclinical models and a first‑in‑human safety cohort. It also demonstrates selective depletion of regulatory T cells in the tumor microenvironment without affecting other T‑cell subsets, confirming the antibody’s proposed mechanism of action.
The publication provides independent, peer‑reviewed evidence that tagmokitug’s pharmacology is robust and supports its use as a platform for combination immunotherapies. The data reinforce the company’s strategy of combining tagmokitug with its approved PD‑1 inhibitor LOQTORZI (toripalimab‑tpzi) and of pursuing multiple solid‑tumor indications, including head‑and‑neck, colorectal, gastric, and esophageal cancers. The findings also strengthen the case for 2026 clinical readouts, which are critical for the company’s valuation and runway.
Coherus reported Q3 2025 earnings on November 6 2025, with net revenue of $11.6 million—below analyst estimates of $13.41 million—and an earnings per share of $(0.38), missing expectations of $(0.36). The company’s PD‑1 asset LOQTORZI generated $11.2 million in Q3 2025 revenue, a 12% quarter‑over‑quarter increase and a 92% year‑over‑year jump, underscoring the commercial momentum behind the combination strategy. Coherus maintains a significant cash reserve that will support its pipeline through the 2025–2026 data milestones.
The announcement was well received by investors, reflecting confidence in the scientific validation of tagmokitug and the company’s broader immuno‑oncology strategy. Management highlighted the importance of the data: Chief Scientific Officer Theresa LaVallee said the publication “provides evidence that tagmokitug has a differentiated profile and a strong potential for combination therapy.” Chairman and CEO Denny Lanfear noted that the company is “moving toward multiple data readouts in 2026 across a number of tumor types.”
Coherus’s focus on pipeline execution, combined with the robust pharmacology demonstrated in the peer‑reviewed study, positions the company to advance tagmokitug toward larger efficacy trials and potential regulatory submission. The publication marks a key milestone in the company’s effort to de‑risk its lead candidate and to capitalize on the growing market for combination immunotherapies in solid tumors.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.